Limits...
Prognostic significance of VEGF expression in patients with bulky cervical carcinoma undergoing neoadjuvant chemotherapy.

Choi CH, Song SY, Choi JJ, Park YA, Kang H, Kim TJ, Lee JW, Kim BG, Lee JH, Bae DS - BMC Cancer (2008)

Bottom Line: Fifteen (51.7%) of 29 patients were scored as VEGF-positive.With logistic regression analysis, VEGF positivity continued to be an independent predictor for poor response (P = 0.032).In addition, the progression-free survival rate was significantly lower in patients with VEGF-positive tumors (P = 0.033).

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Chelhun.choi@samsung.com

ABSTRACT

Background: The prediction of response to treatment would be valuable for managing cervical carcinoma with neoadjuvant chemotherapy.

Methods: To this end, the expression of VEGF was analyzed by immunohistochemistry using paraffin-embedded pre-treatment cervical biopsy tissues. This study included 29 patients with bulky IB to IIA cervical squamous cell carcinoma treated with neoadjuvant chemotherapy.

Results: Fifteen (51.7%) of 29 patients were scored as VEGF-positive. Response to chemotherapy (complete response or residual tumor with less than 3 mm stromal invasion) was observed in eight patients (27.6%), and it was negatively associated with VEGF expression (P = 0.009). With logistic regression analysis, VEGF positivity continued to be an independent predictor for poor response (P = 0.032). In addition, the progression-free survival rate was significantly lower in patients with VEGF-positive tumors (P = 0.033).

Conclusion: Pretreatment assessment of VEGF expression may provide additional information for identification of patients with cervical cancer who had a low likelihood of response to neoadjuvant chemotherapy and an unfavorable prognosis.

Show MeSH

Related in: MedlinePlus

Representative examples of VEGF staining in bulky cervical carcinoma showing cases with no staining (A), weak staining (B), moderate staining (C) and strong staining (D) (×200).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2572070&req=5

Figure 1: Representative examples of VEGF staining in bulky cervical carcinoma showing cases with no staining (A), weak staining (B), moderate staining (C) and strong staining (D) (×200).

Mentions: Figure 1 show representative results of IHC staining. Fifteen (51.7%) of 29 patients were scored as VEGF-positive (Table 1). Table 1 lists the positivity of the proteins according to clinicopathologic characteristics.


Prognostic significance of VEGF expression in patients with bulky cervical carcinoma undergoing neoadjuvant chemotherapy.

Choi CH, Song SY, Choi JJ, Park YA, Kang H, Kim TJ, Lee JW, Kim BG, Lee JH, Bae DS - BMC Cancer (2008)

Representative examples of VEGF staining in bulky cervical carcinoma showing cases with no staining (A), weak staining (B), moderate staining (C) and strong staining (D) (×200).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2572070&req=5

Figure 1: Representative examples of VEGF staining in bulky cervical carcinoma showing cases with no staining (A), weak staining (B), moderate staining (C) and strong staining (D) (×200).
Mentions: Figure 1 show representative results of IHC staining. Fifteen (51.7%) of 29 patients were scored as VEGF-positive (Table 1). Table 1 lists the positivity of the proteins according to clinicopathologic characteristics.

Bottom Line: Fifteen (51.7%) of 29 patients were scored as VEGF-positive.With logistic regression analysis, VEGF positivity continued to be an independent predictor for poor response (P = 0.032).In addition, the progression-free survival rate was significantly lower in patients with VEGF-positive tumors (P = 0.033).

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Chelhun.choi@samsung.com

ABSTRACT

Background: The prediction of response to treatment would be valuable for managing cervical carcinoma with neoadjuvant chemotherapy.

Methods: To this end, the expression of VEGF was analyzed by immunohistochemistry using paraffin-embedded pre-treatment cervical biopsy tissues. This study included 29 patients with bulky IB to IIA cervical squamous cell carcinoma treated with neoadjuvant chemotherapy.

Results: Fifteen (51.7%) of 29 patients were scored as VEGF-positive. Response to chemotherapy (complete response or residual tumor with less than 3 mm stromal invasion) was observed in eight patients (27.6%), and it was negatively associated with VEGF expression (P = 0.009). With logistic regression analysis, VEGF positivity continued to be an independent predictor for poor response (P = 0.032). In addition, the progression-free survival rate was significantly lower in patients with VEGF-positive tumors (P = 0.033).

Conclusion: Pretreatment assessment of VEGF expression may provide additional information for identification of patients with cervical cancer who had a low likelihood of response to neoadjuvant chemotherapy and an unfavorable prognosis.

Show MeSH
Related in: MedlinePlus